Navigation Links
Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis 2016-2017: IPF Pipeline is Very Strong with a Total of 97 Drug Candidates - Research and Markets
Date:3/24/2017

DUBLIN, Mar. 24, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2016" report to their offering.

The IPF pipeline is very strong with a total of 97 drug candidates. Pharma giant such as Asahi Kasei Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the development of the IPF therapeutics. The IPF pipeline comprised of 97 product candidates, of which one is in Phase III stage, 15 are in Phase II stage, 12 are in Phase I stage, 39 are in Pre-clinical stage, and seven are in discovery stage.

SM04646 is under Phase I stage of development by Samumed, LLC for the treatment of IPF. The drug candidate is a small molecule that acts as Wnt pathway modulator. Samumed is using the technology for development of small molecule that modulate Wnt pathway. The technology is not a stem cell therapy, instead focusing on the modulation of the Wnt pathway that recovers and restores the health of diseased tissues and presents significant opportunities in regenerative therapeutics.

Several companies are involved in IPF with their products in different phases. The only Phase III IPF drug candidate is being developed by Asahi Kasei Pharma Corporation. The IPF pipeline drug candidates of Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG and FibroGen, Inc. are in Phase II stage of development. Bristol-Myers Squibb Company is also having its IPF pipeline drug candidates in different clinical stages, including two drugs in Phase II and one drug in Phase I.


Some of the key players developing drug candidates for the treatment of IPF are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Global Blood Therapeutics, Inc., Asahi Kasei Corporation, Beijing Tide Pharmaceutical Co., Limited, FibroGen, Inc., Chong Kun Dang Pharmaceutical Corp., Galapagos NV, Kadmon Holdings, Inc., MediciNova, Inc., and Promedior, Inc.

Key Topics Covered:

1. Research Scope And Methodology

2. Executive Summary

3. Pipeline Outlook

4. Global Idiopathic Pulmonary Fibrosis (Ipf) Pipeline Analysis By Phase (2016)

5. Swot Analysis Of Idiopathic Pulmonary Fibrosis Pipeline

6. Company Profiles And Strategic Developments

7. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/xf6xx2/global_idiopathic

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-idiopathic-pulmonary-fibrosis-ipf-pipeline-analysis-2016-2017-ipf-pipeline-is-very-strong-with-a-total-of-97-drug-candidates---research-and-markets-300429005.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. ... focused on the design, manufacture, sale and distribution of ... on the progress of its commercial roll-out in ... available in more than one hundred (100) medical institutions ... AeroForm offers a needle-free alternative for women who ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month ... bleeding gums in Vancouver, BC, may be developing gingivitis, the first stage of ... and diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants in the ... finding product improvements that could reduce the occurrence of unplanned extubations (UEs). ... breathing or to provide medication. Sometimes, patient movement can cause unplanned extubations which ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage ... featuring seven new products designed to create tailored looks and athleisure-inspired outfits. UA Flex ... cotton easy care stretch twill. , With trendy looks hitting the medical community, UA ...
(Date:6/20/2017)... ... , ... John D'Eri, CEO of Rising Tide Car Wash , will ... during the Autism Society of America 's 49th annual conference to be held ... (DJFF) was founded in 2002 as the nation's first autism organization focused exclusively ...
(Date:6/20/2017)... ... June 20, 2017 , ... International water ... The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health ... world’s water crisis and how it affects the human eyes. , According ...
Breaking Medicine News(10 mins):